Show simple item record

dc.contributor.authorYao, J
dc.contributor.authorFazio, N
dc.contributor.authorSingh, S
dc.contributor.authorBuzzoni, R
dc.contributor.authorCarnaghi, C
dc.contributor.authorWolin, E
dc.contributor.authorTomasek, J
dc.contributor.authorRaderer, M
dc.contributor.authorLahner, H
dc.contributor.authorVoi, M
dc.contributor.authorPacaud, L
dc.contributor.authorLincy, J
dc.contributor.authorSachs, C
dc.contributor.authorValle, Juan W
dc.contributor.authorDelle, F
dc.contributor.authorVan Cutsem, E
dc.contributor.authorTesselaar, M
dc.contributor.authorShimada, Y
dc.contributor.authorOh, D
dc.contributor.authorStrosberg, J
dc.contributor.authorKulke, M
dc.contributor.authorPave, M
dc.date.accessioned2016-01-06T10:08:19Zen
dc.date.available2016-01-06T10:08:19Zen
dc.date.issued2015en
dc.identifier.citationEverolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. 2015, 51 S709-S710 Eur J Canceren
dc.identifier.urihttp://hdl.handle.net/10541/592925en
dc.language.isoenen
dc.titleEverolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Texasen
dc.identifier.journalEuropean Journal of Canceren


This item appears in the following Collection(s)

Show simple item record